Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock

Mosaic ImmunoEngineering Inc.

Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
Initial $15M in common or preferred stock; milestone payments up to $15M more in shares.
Oncotelic to provide operational loan through June 1 and assist in raising $2M initial funding.
If funding fails, transaction may convert to reverse acquisition/merger; shareholder approval required.
Mosaic gains regulatory packages and access to Oncotelic's AI for immunotherapy combination discovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.